October 05, 2023

Navidea Biopharmaceuticals, Inc. Announces NYSE American’s Decision to Suspend Trading In Its Common Stock

August 10, 2023

Navidea Biopharmaceuticals, Inc. NAVB Requests Oral Hearing With NYSE Hearing Panel

July 31, 2023

Navidea Biopharmaceuticals, Inc. Presses Ahead, Embraces Opportunities

July 28, 2023

Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination

July 27, 2023

Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer

July 13, 2023

Navidea Biopharmaceuticals, Inc. Welcomes Dana J Moss, JD to Board of Directors; Amit Bhalla Steps Down

June 30, 2023

Navidea Biopharmaceuticals, Inc. Rejects Unsolicited Offer To Acquire Certain Assets

June 16, 2023

Navidea Biopharmaceuticals, Inc. Announces Distribution of Series K Preferred Stock to Holders of its Common Stock

June 16, 2023

Navidea Biopharmaceuticals, Inc. Receives $7.5 Million Cash from Cardinal Health in Lieu of Contingent Milestone Payment

June 07, 2023

Navidea Biopharmaceuticals, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update

June 02, 2023

Navidea Biopharmaceuticals, Inc. Receives NYSE American Notice

June 01, 2023

Navidea Biopharmaceuticals, Inc. Welcomes Jill Bieker Stefanelli, Ph.D. to Board of Directors; Alexander L. Cappello Steps Down

May 22, 2023

Navidea Biopharmaceuticals, Inc. Investors Purchase $1.1 Million in Preferred Shares at Market

May 11, 2023

Navidea Biopharmaceuticals, Inc. Promotes Michael Sherman Blue, M.D., FACEP, to Chief Medical Officer

May 08, 2023

Navidea Biopharmaceuticals, Inc. Drives Strategy Forward, Shifts Approach for Communications

April 27, 2023

Navidea Biopharmaceuticals, Inc. Announces Intent to sell Cardinal Milestone Payment for $8 Million; Secures New $2.75 Million Equity Line of Credit

April 13, 2023

Navidea Biopharmaceuticals, Inc. Enters Asset Purchase Agreement with Meilleur Technologies, Inc. for Rights to NAV4694

March 30, 2023

Navidea Biopharmaceuticals, Inc. Hires G2G Ventures as Executive Consultants; Chief Medical Officer Steps Down

March 21, 2023

Navidea Biopharmaceuticals Reports Fourth Quarter 2022 Financial Results

March 15, 2023

Navidea Biopharmaceuticals to Host Fourth Quarter 2022 Earnings Conference Call and Business Update

January 03, 2023

Navidea Biopharmaceuticals Announces the Notice of Allowance for U.S. Patent Application for Key Component of the Company’s Cancer Immunotherapy Pipeline

November 30, 2022

Navidea Biopharmaceuticals Files Appeal in CRG Case

November 28, 2022

Navidea Biopharmaceuticals Announces 50th Participant Enrolled in the Company’s Phase 3 Trial in Rheumatoid Arthritis

November 14, 2022

Navidea Biopharmaceuticals Reports Third Quarter 2022 Financial Results

November 07, 2022

Navidea Biopharmaceuticals Announces Details of Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting

November 04, 2022

Navidea Biopharmaceuticals to Host Third Quarter 2022 Earnings Conference Call and Business Update

October 05, 2022

Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting

September 30, 2022

Navidea Biopharmaceuticals Appoints Joshua Wilson to the Board of Directors; Announces Dates Related to its 2022 Annual Meeting of Stockholders

September 15, 2022

Navidea Biopharmaceuticals Announces Presentation of Results from its Two Phase 2B Clinical Trials in Rheumatoid Arthritis at Upcoming American College of Rheumatology Annual Meeting

September 01, 2022

Navidea Biopharmaceuticals Announces Opening of Nine New Sites in its Pivotal Phase 3 Trial in Rheumatoid Arthritis and Termination of Binding Memorandum of Understanding with Jubilant Radiopharma

September 01, 2022

Navidea Biopharmaceuticals Announces Oral Ruling in Case Involving Attorney’s Fees

August 30, 2022

 Navidea Biopharmaceuticals Announces Closing of its Rights Offering and Second Quarter 2022 Earnings Conference Call and Business Update

August 25, 2022

Navidea Biopharmaceuticals Announces Subscriptions of Approximately $14.2 Million from its Rights Offering

August 18, 2022

Navidea Biopharmaceuticals Announces Extension of Subscription Period to August 24, 2022 and Updated Terms of its Previously Announced Rights Offering

August 15, 2022

Navidea Biopharmaceuticals Reports Second Quarter 2022 Financial Results

August 04, 2022

Navidea Biopharmaceuticals Announces Commencement of Rights Offering Subscription Period and Updated Terms of its Previously Announced Rights Offering

August 01, 2022

Navidea Biopharmaceuticals Announces Publication of Study Examining Use of Tc99m Tilmanocept for Lymphatic Mapping and Sentinel Lymph Node Biopsy in Melanoma and Oral Cancer in Australia

August 01, 2022

Navidea Biopharmaceuticals Reminds Investors of Today’s Deadline to be a Shareholder of Record for the Previously Announced Rights Offering

July 25, 2022

Navidea Biopharmaceuticals Announces Publication of Study Examining Tc99m Tilmanocept Imaging of Arterial Inflammation in People with HIV

July 20, 2022

Navidea Biopharmaceuticals Informs Stockholders of Key Dates and Terms Related to Announced Rights Offering

July 05, 2022

Navidea Biopharmaceuticals Announces Additional Bridge Loan Funding

May 24, 2022

Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting

May 23, 2022

Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the Tumor Myeloid-Directed Therapies Summit Annual Meeting

May 12, 2022

Navidea Biopharmaceuticals Reports First Quarter 2022 Financial Results

May 05, 2022

Navidea Biopharmaceuticals to Host First Quarter 2022 Earnings Conference Call and Business Update

April 20, 2022

Navidea Biopharmaceuticals Announces Positive Preliminary Results of Its Ongoing Phase 2B Study Comparing Tc99m Tilmanocept Imaging with Histopathology of Joints from Patients with Rheumatoid Arthritis

April 20, 2022

Navidea Biopharmaceuticals Announces Updated Third-Party Asset Valuation of Tc99m Tilmanocept for Indications in Rheumatoid Arthritis for U.S. and EU Markets

April 19, 2022

Navidea Biopharmaceuticals Announces the Notice of Allowance for U.S. Patent Application for Diagnosis and Treatment of Leishmaniasis

April 18, 2022

Navidea Biopharmaceuticals Announces the Regulatory Approval of Lymphoaim in India

April 12, 2022

Navidea Biopharmaceuticals Announces Adoption of Plan Designed to Protect NOLs and Other Tax Assets, Closing of Bridge Loan Financing, and Business Update Q&A Series